An Australian firm has received the EU’s green light to start clinical trials for a drug produced from stem cells.
Melbourne-based company Mesoblast will assess the safety and efficacy of a drug called Revascor, designed to treat cardiovascular diseases, in 225 patients.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.